Does Melatonin Actually Work for Sleep? What the Evidence Shows

Disclosure & independence
No brand pays for coverage on inareview, and no brand sees an article before it is published. Products are assessed against published criteria, not against what a company would like to read.
At the time of publication, this article contains no affiliate links. If any are added later they will be clearly marked, they will never cost you anything extra, and they cannot change a score: verdicts are decided before any commercial link is considered.
Full details in my affiliate disclosure, editorial policy and testing methodology.
Melatonin has become the first thing millions of people reach for when nights go badly, a trend you can read straight off retail sales data. It sits on open shelves in the United States and Canada, and its image as a natural product is reassuring. The problem is that this reputation as a harmless, universal supplement does not survive long contact with the clinical literature. The question deserves a direct answer: does melatonin actually work to improve sleep, and who does it work for? Here is what the research really says.
The short answer: melatonin works, but in clearly defined situations. Many people use it outside those indications and conclude that it “does nothing” or, conversely, credit it with effects it never really produced.
Does melatonin actually work? What the evidence shows
The meta-analysis by Choi et al. (2022), covering 24 randomised trials, is clear on one central point: in adults with chronic insomnia, melatonin does not produce a statistically significant effect on sleep onset latency, total sleep time or overall sleep efficiency. The CADTH review published the same year, which synthesises seven systematic reviews and two randomised controlled trials, reaches similar conclusions: results are mixed, and the evidence remains of moderate to low quality.
“No significant effect” does not mean “no effect at all”. A dose-response meta-analysis published in 2022, pooling 26 trials, shows a progressive reduction in sleep onset latency and an increase in total sleep time, with the maximum effect observed at around 4 mg per day. In practice, the average gain in falling asleep across those trials stays modest, a matter of a few minutes, which is statistically significant but hard to experience as a decisive change night to night.
That same meta-analysis notes that melatonin’s efficacy is better documented in children and adolescents, and in comorbid insomnia, meaning insomnia that comes alongside another condition. In adults with isolated chronic insomnia, the ratio between benefit and expectation is usually disappointing.
The indications where melatonin has genuinely proved itself
Jet lag is where the evidence for melatonin supplements is strongest. Clinical trials show a real benefit at doses ranging from 0.5 to 5 mg, with a comparable effect across that whole range, and a more pronounced advantage for eastward travel or trips crossing at least five time zones. No regulator in the United States, the United Kingdom or Canada has approved a melatonin product specifically for jet lag, so this use rests on the trial evidence rather than on a licensed indication, a distinction worth keeping in mind.
Delayed sleep phase is the other well-documented indication. This disorder is characterised by a naturally very late sleep onset that cannot be shifted earlier without intervention. Melatonin taken in the evening, several hours before the target bedtime, combined with morning light therapy, has documented efficacy for gradually resetting the circadian rhythm. This is not classic insomnia, and the two are confused constantly.
Who melatonin actually works for: the case of children
In children with neurodevelopmental disorders, some formulations hold a formal marketing authorisation. Slenyto, a paediatric prolonged-release formulation, is licensed in the United Kingdom and across Europe for insomnia in children and adolescents aged 2 to 18 with autism spectrum disorder and/or Smith-Magenis syndrome. Circadin 2 mg is licensed for primary insomnia in adults aged 55 and over; its paediatric use, in conditions such as Angelman syndrome or tuberous sclerosis, falls under separate regulatory and specialist oversight. These uses belong to supervised medical care, not to self-medication.
Melatonin dosage, formulation and timing
Prolonged-release melatonin, sold as Circadin at 2 mg, is indicated for primary insomnia in adults aged 55 and over. It maintains a stable blood level over several hours, which makes it more relevant for night-time awakenings. The immediate-release form acts faster but has a short half-life, better suited to trouble falling asleep than to sleep that breaks up in the middle of the night. Picking the wrong formulation is often the reason a supplement seems to “do nothing”.
Recommended dosage by profile
Regulatory status differs sharply between markets, and it changes what you can actually buy. In the United States, melatonin is sold as a dietary supplement with no premarket approval, in doses that commonly run from 1 mg to 10 mg; independent laboratory analyses have repeatedly found actual melatonin content deviating substantially from the label. One of the few products below that range is Yu Sleep, at 0.9 mg per serving; I explain why that dose is well judged, and why the rest of the formula is not, in my Yu Sleep review. In Canada, it is a licensed Natural Health Product carrying an NPN on the box, available over the counter. In the United Kingdom, melatonin is a prescription-only medicine, so there is no legal over-the-counter supplement route at all. Sleep medicine guidance converges on prolonged-release melatonin at 2 mg, taken one to two hours before bedtime, for three to thirteen weeks in patients aged 55 and over. Outside any medical prescription, starting at 0.5 or 1 mg remains the most prudent dose, and it is also closer to the doses used in the circadian trials than the 5 and 10 mg products that dominate retail shelves. The NIH National Center for Complementary and Integrative Health takes the same cautious line on dosing.
Timing matters as much as the dose. For jet lag, melatonin is taken at bedtime in the destination time zone. For delayed sleep phase, it is used several hours before the target sleep onset. Taking a supplement at any random moment, with no regard for the circadian rhythm, cancels out a large part of its mechanism of action.
Melatonin side effects and interactions you should not ignore
Daytime drowsiness and reduced alertness on waking are the most frequently documented side effects. Mild cognitive effects, difficulty concentrating or remembering, are also reported. Less often, some people report agitation, dizziness or nightmares. Driving the next morning can be affected, particularly in older adults.
The most important drug interactions involve additive sedation: melatonin potentiates the effects of benzodiazepines, Z-drugs, sedating antihistamines and alcohol. Interactions are also reported with some antidepressants and with oral anticoagulants, warfarin in particular: cases of raised INR have appeared in the literature, which justifies closer monitoring when the two are combined. If you take regular medication, speaking to a doctor before starting a melatonin supplement is not an excessive precaution. The NHS melatonin guidance sets out the same interaction warnings.
Health authorities advise against melatonin supplements during pregnancy and breastfeeding, for lack of sufficient clinical data. The same warning applies to people with autoimmune disease and to patients on immunosuppressive treatment. For children, no use should happen without medical advice, outside the strict framework of the licensed indications. In the United States, paediatric melatonin ingestions reported to poison control centres have risen steeply over the past decade, which is a direct consequence of open-shelf availability in gummy form.
What to do if melatonin is not enough, or not right for you
Cognitive behavioural therapy for insomnia (CBT-I) remains the best-validated treatment for chronic insomnia in adults, according to the meta-analyses and to the clinical guidelines of the major sleep medicine societies, which recommend it as first-line care ahead of any medication. Unlike melatonin, CBT-I produces lasting improvements in sleep onset latency, night-time awakenings and overall sleep efficiency, with effects that persist after treatment ends.
If you would rather try a supplement than a therapy, the one with the most recent evidence behind it is magnesium bisglycinate — though it answers a different question from melatonin, and the effect is modest. I go through both trials, the dose that was actually tested and what a night of it costs in my guide to magnesium glycinate for sleep. For the wider picture — valerian, tart cherry, L-theanine and what the published evidence supports for each — see my guide to the best sleep supplements.
Among the techniques used within it: therapeutic sleep restriction, stimulus control and relaxation. Their level of evidence in chronic insomnia is higher than that of any supplement. Morning light therapy, for its part, remains the reference approach for delayed sleep phase.
Insomnia lasting more than three months, combined with severe fatigue, suspected apnoea episodes or significant anxiety, is not something to treat with an over-the-counter supplement. A doctor can refer you to a specialist sleep centre or set up a structured CBT-I programme, a route taken far too rarely, because buying a box off a shelf is simpler.
If melatonin still makes sense for your profile, the manufacturer’s quality, the formulation and the dose all matter. At inareview, melatonin products are assessed on their label, dose, evidence and price per serving against a published rubric, and no brand can influence the result.
What to keep in mind before taking melatonin
So, does melatonin actually work? Yes, but only within clearly defined indications. Its efficacy for jet lag is the best established. It is useful for delayed sleep phase, combined with morning light therapy. In certain comorbid insomnias, and in children with a recognised neurodevelopmental disorder, a modest benefit is documented. Its impact on chronic insomnia in otherwise healthy adults, by contrast, remains weak: the American Academy of Sleep Medicine suggests, in its clinical practice guideline, that clinicians not use melatonin for sleep-onset or sleep-maintenance insomnia in adults. It is not a universal sleeping pill.
The real problem is not melatonin itself. It is the undifferentiated way it gets used, with no regard for the profile, the dose, the formulation or the actual indication. A supplement that makes sense for jet lag is not necessarily right for chronic insomnia driven by anxiety. These situations are not alike and are not treated the same way.
Before choosing, identifying the exact nature of your sleep problem is the first useful step. If a melatonin supplement does turn out to suit your situation, the independent reviews on inareview let you compare the serious formulas, at the right dose, with full transparency on the evaluation method.
Sources
The doses, indications and warnings above are taken from these four documents, so you can read them for yourself.
- NIH National Center for Complementary and Integrative Health — Melatonin: What You Need To Know — where melatonin has been shown to help, where the evidence runs out, and the cautious line on dosing.
- NHS — Melatonin, a hormone used for sleep problems — the interaction warnings, and the advice against use in pregnancy and breastfeeding.
- Sateia et al. (2017) — American Academy of Sleep Medicine clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults — the recommendation that clinicians not use melatonin for sleep-onset or sleep-maintenance insomnia, graded weak.
- Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug (Journal of Pineal Research, 2024) — the dose-response and timing analysis behind the advice to start low and take it well before bedtime rather than at lights-out.

